1. Home
  2. RCUS vs NRP Comparison

RCUS vs NRP Comparison

Compare RCUS & NRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • NRP
  • Stock Information
  • Founded
  • RCUS 2015
  • NRP 2002
  • Country
  • RCUS United States
  • NRP United States
  • Employees
  • RCUS N/A
  • NRP N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • NRP Coal Mining
  • Sector
  • RCUS Health Care
  • NRP Energy
  • Exchange
  • RCUS Nasdaq
  • NRP Nasdaq
  • Market Cap
  • RCUS 1.2B
  • NRP 1.4B
  • IPO Year
  • RCUS 2018
  • NRP N/A
  • Fundamental
  • Price
  • RCUS $13.90
  • NRP $107.00
  • Analyst Decision
  • RCUS Buy
  • NRP
  • Analyst Count
  • RCUS 7
  • NRP 0
  • Target Price
  • RCUS $22.00
  • NRP N/A
  • AVG Volume (30 Days)
  • RCUS 937.9K
  • NRP 23.3K
  • Earning Date
  • RCUS 11-05-2025
  • NRP 11-04-2025
  • Dividend Yield
  • RCUS N/A
  • NRP 2.79%
  • EPS Growth
  • RCUS N/A
  • NRP N/A
  • EPS
  • RCUS N/A
  • NRP 10.64
  • Revenue
  • RCUS $262,000,000.00
  • NRP $219,503,000.00
  • Revenue This Year
  • RCUS N/A
  • NRP N/A
  • Revenue Next Year
  • RCUS N/A
  • NRP N/A
  • P/E Ratio
  • RCUS N/A
  • NRP $10.05
  • Revenue Growth
  • RCUS 6.07
  • NRP N/A
  • 52 Week Low
  • RCUS $6.50
  • NRP $86.83
  • 52 Week High
  • RCUS $18.98
  • NRP $113.04
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 68.53
  • NRP 65.32
  • Support Level
  • RCUS $12.89
  • NRP $105.55
  • Resistance Level
  • RCUS $16.12
  • NRP $109.76
  • Average True Range (ATR)
  • RCUS 0.73
  • NRP 2.21
  • MACD
  • RCUS 0.07
  • NRP 0.49
  • Stochastic Oscillator
  • RCUS 44.17
  • NRP 69.93

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About NRP Natural Resource Partners LP Limited Partnership

Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.

Share on Social Networks: